An observational study in Atrial Fibrillation, sponsored by National Medical Research Center for Therapy and Preventive Medicine. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by National Medical Research Center for Therapy and Preventive Medicine · Observational
The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses. The aim of this study is to reveal the specific biomarkers by antibody microarrays.
One hundred twenty patients with atrial fibrillation will participate in the study.
They will be divided into three groups.
Groups would be formed from patients who previously underwent atrial fibrillation ablations and whose blood samples have been taken and placed in a biobank before interventional treatment. The first step will include proteomic serum profiling using antibody microarrays in ten subjects will be split into 3 groups. The second step will include validation of selected protein biomarkers, in the total cohort (N=120).
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 120 is below the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →National Medical Research Center for Therapy and Preventive Medicine is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients 18-85 years old with s paroxismal or persistant atrial fibrillation and prior interventional treatment
Exclusion Criteria:
Diagnostic Test: Proteomic analysis by antibody microarrays
Diagnostic Test: Proteomic analysis by antibody microarrays
Diagnostic Test: Proteomic analysis by antibody microarrays
Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
proteins after validation
number of protein which will be specific for non-PV associated arrhythmic focuses group after validation
Time frame: 1 year
proteins after screening
number of protein which will be specific for non-PV associated arrhythmic focuses group after screening
Time frame: 1 year
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Medical Research Center for Therapy and Preventive Medicine